PL3325509T3 - Przeciwciała anty-TfR oraz ich zastosowanie w leczeniu zaburzeń proliferacyjnych i zapalnych - Google Patents
Przeciwciała anty-TfR oraz ich zastosowanie w leczeniu zaburzeń proliferacyjnych i zapalnychInfo
- Publication number
- PL3325509T3 PL3325509T3 PL16744353T PL16744353T PL3325509T3 PL 3325509 T3 PL3325509 T3 PL 3325509T3 PL 16744353 T PL16744353 T PL 16744353T PL 16744353 T PL16744353 T PL 16744353T PL 3325509 T3 PL3325509 T3 PL 3325509T3
- Authority
- PL
- Poland
- Prior art keywords
- proliferative
- treatment
- inflammatory disorders
- tfr antibodies
- tfr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15306192 | 2015-07-22 | ||
| PCT/EP2016/067465 WO2017013230A1 (en) | 2015-07-22 | 2016-07-21 | ANTI-TfR ANTIBODIES AND THEIR USE IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS |
| EP16744353.0A EP3325509B1 (en) | 2015-07-22 | 2016-07-21 | Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3325509T3 true PL3325509T3 (pl) | 2021-07-19 |
Family
ID=53776520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16744353T PL3325509T3 (pl) | 2015-07-22 | 2016-07-21 | Przeciwciała anty-TfR oraz ich zastosowanie w leczeniu zaburzeń proliferacyjnych i zapalnych |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11230605B2 (enExample) |
| EP (1) | EP3325509B1 (enExample) |
| JP (1) | JP6858185B2 (enExample) |
| KR (1) | KR102690998B1 (enExample) |
| CN (1) | CN107849136B (enExample) |
| AU (1) | AU2016296321B2 (enExample) |
| CA (1) | CA2992509C (enExample) |
| CY (1) | CY1123941T1 (enExample) |
| DK (1) | DK3325509T3 (enExample) |
| ES (1) | ES2860988T3 (enExample) |
| HR (1) | HRP20210393T1 (enExample) |
| HU (1) | HUE053296T2 (enExample) |
| IL (1) | IL257065B (enExample) |
| LT (1) | LT3325509T (enExample) |
| MX (1) | MX2018000569A (enExample) |
| PL (1) | PL3325509T3 (enExample) |
| PT (1) | PT3325509T (enExample) |
| RS (1) | RS61586B1 (enExample) |
| RU (1) | RU2737637C2 (enExample) |
| SI (1) | SI3325509T1 (enExample) |
| SM (1) | SMT202100134T1 (enExample) |
| WO (1) | WO2017013230A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI787796B (zh) | 2015-05-04 | 2022-12-21 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法 |
| FR3062213B1 (fr) | 2017-01-20 | 2021-02-26 | Endodiag | Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose |
| EP3552631A1 (en) * | 2018-04-10 | 2019-10-16 | Inatherys | Antibody-drug conjugates and their uses for the treatment of cancer |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12595310B2 (en) | 2019-11-06 | 2026-04-07 | The Regents Of The University Of California | Compositions and methods for transferrin receptor 1 targeting |
| IL295022A (en) * | 2020-01-31 | 2022-09-01 | Dyne Therapeutics Inc | Antibody against transferrin receptor and uses thereof |
| WO2021154477A1 (en) | 2020-01-31 | 2021-08-05 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| US12629426B2 (en) * | 2020-07-23 | 2026-05-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) * | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11969475B2 (en) * | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| WO2023283623A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| CA3230796A1 (en) | 2021-09-01 | 2023-03-09 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
| TW202330601A (zh) * | 2021-09-13 | 2023-08-01 | 德州大學系統董事會 | ＴｆＲ抗原結合蛋白及其用途 |
| IL316143A (en) * | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| KR20250114322A (ko) * | 2022-12-02 | 2025-07-29 | 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 | 항-tfr1 항체 및 이의 용도 |
| TW202444759A (zh) | 2023-03-24 | 2024-11-16 | 美商戴納立製藥公司 | Ａβ靶向蛋白及使用方法 |
| EP4477236A1 (en) | 2023-06-14 | 2024-12-18 | Inatherys | Combination therapy for treating a tumor using adc comprising anti-cd71 antibodies and bh3 mimetics |
| IL327952A (en) * | 2023-10-26 | 2026-06-01 | Biogen Ma Inc | Anti-transferrin receptor antibodies and uses thereof |
| WO2025140522A1 (en) * | 2023-12-29 | 2025-07-03 | Nona Biosciences (Suzhou) Co., Ltd. | Anti-tfr1 antibodies, preparation methods and uses thereof |
| CN121517563A (zh) * | 2024-08-09 | 2026-02-13 | 东北制药集团股份有限公司 | 人源化的靶向TfR1的抗体及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4434156A (en) | 1981-10-26 | 1984-02-28 | The Salk Institute For Biological Studies | Monoclonal antibodies specific for the human transferrin receptor glycoprotein |
| HUP0104865A3 (en) * | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| ES2369542T3 (es) | 2002-07-31 | 2011-12-01 | Seattle Genetics, Inc. | Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa. |
| WO2005011082A2 (en) | 2003-07-23 | 2005-02-03 | Univeral Infusion Technology | Drive motor transmission system |
| EP1740616B1 (en) | 2004-04-30 | 2011-12-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-tfr antibody. |
| KR101295139B1 (ko) * | 2004-06-07 | 2013-08-12 | 레이븐 바이오테크놀로지스, 인코퍼레이티드 | 트랜스페린 리셉터 항체 |
| EP3530736A3 (en) * | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| FR2953841B1 (fr) * | 2009-12-16 | 2011-12-30 | Centre Nat Rech Scient | Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer |
| JP2015524816A (ja) * | 2012-08-02 | 2015-08-27 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | サラセミアを処置するためのトランスフェリンレセプターアンタゴニストの使用 |
| DK2918603T3 (en) * | 2012-11-08 | 2018-10-15 | Univ Miyazaki | ANTIBODY STANDING TO SPECIFICALLY RECOGNIZE TRANSFERRIN RECEPTOR |
| EP3552631A1 (en) * | 2018-04-10 | 2019-10-16 | Inatherys | Antibody-drug conjugates and their uses for the treatment of cancer |
-
2016
- 2016-07-21 IL IL257065A patent/IL257065B/en unknown
- 2016-07-21 PT PT167443530T patent/PT3325509T/pt unknown
- 2016-07-21 CA CA2992509A patent/CA2992509C/en active Active
- 2016-07-21 RS RS20210280A patent/RS61586B1/sr unknown
- 2016-07-21 MX MX2018000569A patent/MX2018000569A/es unknown
- 2016-07-21 WO PCT/EP2016/067465 patent/WO2017013230A1/en not_active Ceased
- 2016-07-21 AU AU2016296321A patent/AU2016296321B2/en active Active
- 2016-07-21 DK DK16744353.0T patent/DK3325509T3/da active
- 2016-07-21 US US15/746,590 patent/US11230605B2/en active Active
- 2016-07-21 JP JP2018522867A patent/JP6858185B2/ja active Active
- 2016-07-21 HU HUE16744353A patent/HUE053296T2/hu unknown
- 2016-07-21 KR KR1020187004745A patent/KR102690998B1/ko active Active
- 2016-07-21 SM SM20210134T patent/SMT202100134T1/it unknown
- 2016-07-21 ES ES16744353T patent/ES2860988T3/es active Active
- 2016-07-21 EP EP16744353.0A patent/EP3325509B1/en active Active
- 2016-07-21 LT LTEP16744353.0T patent/LT3325509T/lt unknown
- 2016-07-21 RU RU2018106364A patent/RU2737637C2/ru active
- 2016-07-21 PL PL16744353T patent/PL3325509T3/pl unknown
- 2016-07-21 HR HRP20210393TT patent/HRP20210393T1/hr unknown
- 2016-07-21 SI SI201631117T patent/SI3325509T1/sl unknown
- 2016-07-21 CN CN201680040714.2A patent/CN107849136B/zh active Active
-
2021
- 2021-03-09 CY CY20211100200T patent/CY1123941T1/el unknown
- 2021-12-09 US US17/546,208 patent/US12037408B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3325509T (lt) | Anti-tfr antikūnai ir jų panaudojimas proliferacinių ir uždegiminių sutrikimų gydymui | |
| IL279752B (en) | Polycyclic compounds and use thereof in the treatment of immune disorders | |
| IL259747A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
| IL262092A (en) | Humanized anti-pacap antibodies and uses thereof | |
| SI3258951T1 (sl) | Anti-pvrig protitelesa in metode uporabe | |
| SI3240554T1 (sl) | Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni | |
| IL259441A (en) | Materials and methods for treatment of titin-based myopathies and other titinopaties | |
| HUE061761T2 (hu) | Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében | |
| PT2953969T (pt) | Anticorpos anti-il-17a e utilização dos mesmos no tratamento de distúrbios autoimunes e inflamatórios | |
| SI3303394T1 (sl) | Protitelesa proti-CTLA-4 in postopki njihove uporabe | |
| PL3303396T3 (pl) | Przeciwciała przeciwko ox40 i ich zastosowanie | |
| PL3353210T3 (pl) | Przeciwciała anty-TIGIT i sposoby stosowania | |
| PL3114145T3 (pl) | Przeciwciała przeciw ludzkiemu białku pomocniczemu receptora interleukiny-1 (il1rap) i ich zastosowania | |
| PL3250610T3 (pl) | Przeciwciała anty-FcRn i sposoby ich stosowania | |
| PL3215532T3 (pl) | Przeciwciała anty-TIM3 i sposoby ich zastosowania | |
| LT3472183T (lt) | Adeno-asocijuotų virusų variantai ir jų panaudojimo būdai | |
| PL3481846T3 (pl) | 11-podstawione 24-hydroksysterole do stosowania w leczeniu stanów związanych z NMDA | |
| PL3512517T3 (pl) | Stosowanie pridopidyny w leczeniu lęku i depresji | |
| HRP20180260T1 (hr) | Dimer buprenorfina i njegova uporaba u liječenju gastrointestinalnih poremećaja | |
| SI3359563T1 (sl) | Antigen receptorji in njih uporaba | |
| PL3236960T3 (pl) | Fluralaner do zastosowania w leczeniu demodekozy | |
| PL3229794T3 (pl) | Kombinacja farmaceutyczna obejmująca ponesimod i jej zastosowanie w leczeniu stwardnienia rozsianego | |
| HUE058314T2 (hu) | Pridopidin alkalmazása Rett-szindróma kezelésére | |
| IL251904B (en) | Apilimod for use in the treatment of melanoma | |
| PL3592355T3 (pl) | Kx2-391/kx-01 do zastosowania w leczeniu rogowacenia słonecznego |